Avacta: Develops next-gen biologics using its proprietary Affimer® platform technology. It is based on a naturally occurring human protein, engineered to behave like an antibody, but smaller, simpler, more robust, easy to format, cheaper and quicker to produce, highly specific to the target and non-immunogenic. Lead assets are PD-L1/LAG-3 single molecule bispecific inhibitor and a PD-L1 tumour microenvironment targeted innate immune activators (I-DASH inhibitors, STING agonists). First-in-man data exp. in 2020. Partnerships with Moderna and OncoSec (Gene delivery), Memorial Sloan Kettering (CAR-T), Iksuda and Tufts University (Drug conjugates). Affimer reagents business for Dx and research.
Sector/industry:
Healthcare/Medical Devices
Characteristics:
Clinical Stage
Pre-Clinical Stage
Disease Space
Immuno-Oncology
Listing
Europe, Public
Market Cap
<100MM
Therapeutic Modalities
Platform Technology
Website:
Address:
United Kingdom

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

European Biotech Investor Day 2019

New York City, August 1, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.